Zydus Lifesciences receives final USFDA approval for Cevimeline Hydrochloride Capsules 30mg

Zydus Lifesciences Limited has received final approval from the USFDA for Cevimeline Hydrochloride Capsules 30mg. The capsules are indicated for the symptomatic treatment of dry mouth associated with Sjogren’s syndrome. Cevimeline is a muscarinic receptor agonist that stimulates salivary secretion. The annual sales of the drug were USD 26.9 mn. Zydus now has 436 approvals and has filed 505 ANDAs since FY 2003-04. The capsules will be produced at the Group’s manufacturing facility at SEZ-1I, Ahmedabad.